AMPLITUDE: Niraparib + Abiraterone/Prednisone + ADT in BRCA2-Mutated mCSPC

Authored by Natalia Gandur, published on 2026-07-24 03:00:50.0

The algorithm is broadly aligned with current mCSPC practice for diagnosis, early treatment intensification with AR pathway inhibitors, and routine consideration of germline/somatic testing. However, use of niraparib + abiraterone/prednisone + ADT specifically in mCSPC is not yet an established standard of care in most guidelines (as of recent public evidence), and is best framed as clinical-trial driven or dependent on local regulatory approval. The safety/monitoring and sequencing concepts are consistent with PARP inhibitor class use and prostate cancer care pathways.

  1. 1. Confirm metastatic castration-sensitive prostate cancer (mCSPC)
    This pathway applies to patients with metastatic castration-sensitive prostate cancer (mCSPC) with an HRR alteration being considered for first-line treatment intensification. Confirm: - Metastatic prostate cancer - Castration-sensitive disease state - Ongoing ADT or planned ADT initiation - Disease volume / burden and symptoms - Visceral disease, bone disease, pain, and need for response - Prior local therapy, systemic therapy, docetaxel, or ARPI exposure if any - Performance status, frailty, comorbidities, and patient goals ADT is the backbone of treatment for mCSPC. Confirm that a GnRH agonist/antagonist is ongoing or planned, or that the patient has had prior bilateral orchiectomy. Supportive care considerations: - Bone health and fracture risk - Calcium/vitamin D according to local practice - DEXA / bone health assessment when appropriate - Bone-protective therapy when indicated - Pain control and skeletal event prevention - Cardiovascular and metabolic risk optimization This is an mCSPC pathway, not an mCRPC pathway.
    • 2. Order or confirm early germline and/or somatic HRR testing
      Confirm germline and/or somatic testing for homologous recombination repair (HRR) alterations early in the metastatic prostate cancer treatment pathway. Testing may include: - Tissue-based tumor testing - Circulating tumor DNA testing - Germline testing when appropriate Document: - Gene involved - Germline vs somatic status - Copy-number loss/deletion when available - Monoallelic vs biallelic status when available - Whether the alteration is clearly treatment-driving under local guidance BRCA1/2 alterations are the highest-priority HRR alterations for treatment selection. Non-BRCA HRR alterations should be interpreted with caution and in the context of the trial population, clinical evidence, access, and expert review. If cfDNA is negative or indeterminate and clinical suspicion remains high, consider tissue testing when feasible.
      • 3. HRR alteration present?
        If an eligible HRR alteration is present, proceed to assess suitability for niraparib + abiraterone/prednisone + ADT. If no HRR alteration is present, or testing is negative/indeterminate, use a standard mCSPC treatment-selection pathway. Consider: - Standard ARPI-based intensification - Docetaxel or triplet therapy when appropriate - Clinical trial - Tissue testing if cfDNA is negative/indeterminate and suspicion remains high - Germline testing if not previously performed Do not use niraparib + abiraterone solely because HRR status is unknown.
        • Assess suitability for abiraterone/prednisone + ADT
          Assess whether the patient is clinically suitable for abiraterone/prednisone + ADT. Consider: - Blood pressure control - Baseline potassium - Liver function - Cardiovascular history - Heart failure or fluid retention risk - Edema risk - Diabetes or steroid-related risk - Medication interactions - Ability to take prednisone/prednisolone as prescribed - Patient preference, access, and adherence Abiraterone-related toxicity considerations: - Hypertension - Hypokalemia - Fluid retention / edema - Liver enzyme elevation - Hyperglycemia or steroid-related effects - Cardiovascular risk If abiraterone/prednisone is not suitable, use another standard mCSPC intensification pathway or clinical trial.
          • 4. Fit for abiraterone/prednisone + ADT?
            Proceed only if abiraterone/prednisone + ADT is clinically feasible. Favorable criteria:- Blood pressure is controlled or manageable- Potassium is normal or correctable- Liver function is acceptable- Cardiovascular and edema risks are acceptable or manageable- Prednisone/prednisolone use is appropriate- Patient can comply with monitoring and oral therapy If not fit, use an alternative standard mCSPC intensification pathway.
            • Use another standard mCSPC intensification pathway
              Use another standard mCSPC intensification pathway when HRR status is negative/unknown or when niraparib + abiraterone/prednisone is not clinically appropriate. This is a terminal hand-off node, not a loop. Treatment selection should be based on disease volume, symptoms, prior therapy, frailty, comorbidities, toxicity risk, access, and patient goals.
            • PARP safety and access gate
              Before adding niraparib, assess PARP inhibitor safety, feasibility, and access. Consider: - Baseline hemoglobin and marrow reserve - Baseline platelet count - Neutrophil count and infection risk - Prior chemotherapy or radiotherapy - Renal function - Frailty, fatigue risk, and functional status - Bleeding/bruising risk - Transfusion history or baseline cytopenias - Rare MDS/AML risk discussion - Regulatory approval, payer/access requirements, and local guidance In patients with preexisting anemia, thrombocytopenia, or borderline marrow reserve, consider closer early CBC monitoring and correct reversible contributors when feasible.
              • Consider niraparib + abiraterone/prednisone + ADT
                For selected patients with HRR-altered mCSPC, niraparib + abiraterone/prednisone + ADT may be considered when supported by trial evidence, regulatory approval/access, and expert clinical judgment. Frame as: - Trial-based - Practice-informing - Access-dependent - Not necessarily universally adopted as standard of care unless supported by local approval/guidelines Dosing should follow prescribing information, study protocol, or local guidance. Typical regimen framework: - Niraparib + abiraterone acetate oral therapy - Prednisone or prednisolone according to protocol/local label - Ongoing ADT with GnRH analog or prior bilateral orchiectomy Before starting: - CBC with differential and platelets - Renal function - Liver tests - Potassium - Blood pressure - Cardiovascular and edema assessment - Medication interaction review - Baseline anemia/thrombocytopenia assessment - Patient counseling regarding hematologic toxicity, hypertension, hypokalemia, fluid retention, fatigue, nausea, and monitoring needs
                • 6. Monitor
                  Suggested monitoring: - CBC with differential and platelets at baseline and early during treatment, then periodically or as clinically indicated - Hemoglobin trajectory, symptoms of anemia, transfusion need - Platelet count and bleeding/bruising symptoms - Neutrophil count, infection risk, fever - Blood pressure - Potassium - Liver tests - Renal function - Fluid retention / edema - Fatigue, nausea, appetite, functional status - Adherence and medication interactions - PSA trend, symptoms, and imaging response according to clinical context PARP inhibitor toxicity considerations: - Anemia - Thrombocytopenia - Neutropenia - Fatigue - Nausea - Rare MDS/AML risk Abiraterone/prednisone toxicity considerations: - Hypertension - Hypokalemia - Fluid retention / edema - Liver enzyme elevation - Hyperglycemia or steroid-related effects - Cardiovascular risk If significant cytopenias develop: - Hold or interrupt niraparib according to severity and prescribing information/local protocol - Monitor CBC closely until recovery - Resume at a reduced dose when appropriate - Evaluate reversible contributors such as bleeding, nutritional deficiency, renal dysfunction, marrow reserve, and disease progression - Provide transfusion/supportive care when clinically indicated If hypertension, hypokalemia, fluid retention, or liver test abnormalities develop: - Optimize blood pressure control - Correct potassium - Reassess mineralocorticoid-related toxicity - Hold or adjust therapy according to severity and prescribing information/local protocol - Reassess cardiovascular risk and prednisone adherence
                  • 7. At progression: re-stage and move to next-line sequencing / clinical trials
                    At radiographic, clinical, or PSA progression, reassess the full disease context. Confirm: - Castration-resistant transition - Castrate testosterone level - Prior PARP inhibitor exposure - Prior abiraterone / ARPI exposure - Prior docetaxel exposure - Taxane suitability - PSMA PET / radioligand therapy eligibility when relevant - Molecular profile and whether repeat testing is useful - Clinical trial eligibility - Symptoms, disease tempo, visceral disease, and patient goals Terminal hand-off: Open mCRPC treatment-selection or post-PARP / post-ARPI sequencing pathway when available. Avoid looping back within this algorithm; progression should trigger reassessment and next-line pathway selection. Key clinical caveats: - AMPLITUDE evaluates PARP + ARPI intensification earlier in the disease course for HRR-altered mCSPC. - This pathway should be framed as trial-based, practice-informing, and access-dependent unless local approval/guidelines support routine use. - BRCA1/2 alterations are the highest-priority HRR alterations; non-BRCA HRR alterations require careful interpretation. - Baseline marrow reserve is critical because anemia, thrombocytopenia, and neutropenia are key implementation issues. - Abiraterone-related monitoring remains essential: blood pressure, potassium, liver tests, edema/fluid retention, cardiovascular risk, and steroid-related effects. - Use should be individualized according to regulatory approval, access, toxicity risk, prior therapy, patient goals, and expert review.
            • 5. Eligible and available?
              Proceed if: - mCSPC is confirmed- ADT/castration backbone is maintained- A clinically relevant HRR alteration is present- Patient is an appropriate candidate for PARP + ARPI intensification- Baseline marrow reserve is acceptable or manageable- Blood pressure, potassium, liver function, and cardiovascular risk are acceptable or manageable- Prednisone use is appropriate- Access/regulatory status supports use- Patient understands expected benefits, monitoring burden, and toxicity risks If not eligible or not available, use a standard mCSPC pathway, clinical trial, or alternative treatment strategy.
              • Alternative standard mCSPC treatment
                Use an alternative standard mCSPC treatment strategy when niraparib + abiraterone/prednisone is not suitable, feasible, available, or supported by local guidance. Consider: - ADT + ARPI - ADT + docetaxel in selected patients - Triplet therapy in appropriate high-volume/high-risk settings - Clinical trial - Symptom burden, disease volume, visceral disease, frailty, comorbidities, toxicity profile, access, and patient goals Terminal hand-off:Open standard mCSPC intensification pathway when available.
              • Consider niraparib + abiraterone/prednisone + ADT
                For selected patients with HRR-altered mCSPC, niraparib + abiraterone/prednisone + ADT may be considered when supported by trial evidence, regulatory approval/access, and expert clinical judgment. Frame as: - Trial-based - Practice-informing - Access-dependent - Not necessarily universally adopted as standard of care unless supported by local approval/guidelines Dosing should follow prescribing information, study protocol, or local guidance. Typical regimen framework: - Niraparib + abiraterone acetate oral therapy - Prednisone or prednisolone according to protocol/local label - Ongoing ADT with GnRH analog or prior bilateral orchiectomy Before starting: - CBC with differential and platelets - Renal function - Liver tests - Potassium - Blood pressure - Cardiovascular and edema assessment - Medication interaction review - Baseline anemia/thrombocytopenia assessment - Patient counseling regarding hematologic toxicity, hypertension, hypokalemia, fluid retention, fatigue, nausea, and monitoring needs
                • 6. Monitor
                  Suggested monitoring: - CBC with differential and platelets at baseline and early during treatment, then periodically or as clinically indicated - Hemoglobin trajectory, symptoms of anemia, transfusion need - Platelet count and bleeding/bruising symptoms - Neutrophil count, infection risk, fever - Blood pressure - Potassium - Liver tests - Renal function - Fluid retention / edema - Fatigue, nausea, appetite, functional status - Adherence and medication interactions - PSA trend, symptoms, and imaging response according to clinical context PARP inhibitor toxicity considerations: - Anemia - Thrombocytopenia - Neutropenia - Fatigue - Nausea - Rare MDS/AML risk Abiraterone/prednisone toxicity considerations: - Hypertension - Hypokalemia - Fluid retention / edema - Liver enzyme elevation - Hyperglycemia or steroid-related effects - Cardiovascular risk If significant cytopenias develop: - Hold or interrupt niraparib according to severity and prescribing information/local protocol - Monitor CBC closely until recovery - Resume at a reduced dose when appropriate - Evaluate reversible contributors such as bleeding, nutritional deficiency, renal dysfunction, marrow reserve, and disease progression - Provide transfusion/supportive care when clinically indicated If hypertension, hypokalemia, fluid retention, or liver test abnormalities develop: - Optimize blood pressure control - Correct potassium - Reassess mineralocorticoid-related toxicity - Hold or adjust therapy according to severity and prescribing information/local protocol - Reassess cardiovascular risk and prednisone adherence
                  • 7. At progression: re-stage and move to next-line sequencing / clinical trials
                    At radiographic, clinical, or PSA progression, reassess the full disease context. Confirm: - Castration-resistant transition - Castrate testosterone level - Prior PARP inhibitor exposure - Prior abiraterone / ARPI exposure - Prior docetaxel exposure - Taxane suitability - PSMA PET / radioligand therapy eligibility when relevant - Molecular profile and whether repeat testing is useful - Clinical trial eligibility - Symptoms, disease tempo, visceral disease, and patient goals Terminal hand-off: Open mCRPC treatment-selection or post-PARP / post-ARPI sequencing pathway when available. Avoid looping back within this algorithm; progression should trigger reassessment and next-line pathway selection. Key clinical caveats: - AMPLITUDE evaluates PARP + ARPI intensification earlier in the disease course for HRR-altered mCSPC. - This pathway should be framed as trial-based, practice-informing, and access-dependent unless local approval/guidelines support routine use. - BRCA1/2 alterations are the highest-priority HRR alterations; non-BRCA HRR alterations require careful interpretation. - Baseline marrow reserve is critical because anemia, thrombocytopenia, and neutropenia are key implementation issues. - Abiraterone-related monitoring remains essential: blood pressure, potassium, liver tests, edema/fluid retention, cardiovascular risk, and steroid-related effects. - Use should be individualized according to regulatory approval, access, toxicity risk, prior therapy, patient goals, and expert review.
        • No/Unknown
          If HRR status is negative, unknown, or indeterminate, do not select niraparib + abiraterone/prednisone solely on the basis of missing biomarker information. Use a standard mCSPC treatment-selection pathway and consider repeat or tissue-based testing when clinically appropriate.
          • Standard mCSPC treatment pathway
            For patients without a qualifying HRR alteration, use standard mCSPC treatment selection. Consider: - ADT + ARPI - ADT + docetaxel in selected patients - Triplet therapy in appropriate high-volume/high-risk settings - Clinical trial - Disease volume, symptoms, visceral disease, frailty, comorbidities, access, and patient preference Terminal hand-off: Open the standard mCSPC intensification pathway when available.For patients without known HRR alterations (or when PARP use is not indicated/available), standard mCSPC care is ADT with treatment intensification (ARPI and/or docetaxel; selected patients may receive triplet therapy).
tosprivacy